Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT05051943 Completed - Clinical trials for Rheumatoid Arthritis

A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response

OPALE
Start date: September 29, 2020
Phase:
Study type: Observational

The aim of the study is to describe the real-world profile of patients treated with adalimumab FK in gastroenterology, dermatology or rheumatology in order to evaluate in this population the predictive factors of therapeutic response (in particular nutritional status) and generate hypothesis between nutritional status and therapeutic response.

NCT ID: NCT05046899 Completed - Plaque Psoriasis Clinical Trials

Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis.

Start date: September 14, 2021
Phase: N/A
Study type: Interventional

The purpose of this investigation is to assess performance and safety of BIOpH+ Psoriasis Medical Bath in comparison to a comparative device.

NCT ID: NCT05028582 Completed - Scalp Psoriasis Clinical Trials

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

ARRECTOR
Start date: August 24, 2021
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of ARQ-154 foam vs vehicle applied once daily for 8 weeks by subjects with scalp and body psoriasis.

NCT ID: NCT05020249 Completed - Clinical trials for Moderate to Severe Plaque Psoriasis

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Start date: September 27, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.

NCT ID: NCT05003531 Completed - Psoriasis Clinical Trials

A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Start date: September 23, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of IBI112 administered in different dose regimens for the treatment of patients with plaque psoriasis

NCT ID: NCT04999839 Completed - Clinical trials for Moderate to Severe Plaque Psoriasis

Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

Start date: August 11, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with moderate to severe plaque psoriasis. This study will also evaluate the plasma concentrations of NDI-034858 and explore the immune response to NDI-034858 in participants with moderate to severe plaque psoriasis.

NCT ID: NCT04989296 Completed - Psoriasis Vulgaris Clinical Trials

Informative Value of Determining the Level of NF-κB Translocation in Lymphocyte Populations in Children With Psoriasis

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

This study is the first to quantify the level of NF-kB translocation in lymphocyte populations in children and adolescents with psoriasis of varying severity.

NCT ID: NCT04975295 Completed - Psoriasis Clinical Trials

A Study of LY3361237 in Participants With Psoriasis

Start date: July 27, 2021
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to learn more about the safety and tolerability of LY3361237 and any side effects that might be associated with it when given to participants with psoriasis. LY3361237 will be administered by injections just under the skin. The study will last up to 41 weeks and may include up to 15 visits to the study center.

NCT ID: NCT04967508 Completed - Psoriasis Clinical Trials

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

Start date: July 6, 2021
Phase: Phase 3
Study type: Interventional

This is a randomised, double-blind, multicentre clinical study to evaluate the efficacy, safety, tolerability, PK, and immunogenicity of SB17 compared to Stelara® in subjects with moderate to severe plaque psoriasis.

NCT ID: NCT04930042 Completed - Psoriasis Clinical Trials

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

Start date: June 3, 2021
Phase: Phase 3
Study type: Interventional

Safety and Efficacy study of AVT04 (Alvotech Biosimilar to Ustekinumab), in patients with moderate to severe plaque psoriasis